Table III.

Non-hematologic toxicities possibly attributable to decitabine and/or vorinostat during cycle 1: concurrent schedule (n = 20).

	Dose level 1 (n = 3)		Dose level 2 (n = 10)		Dose level 3 (n = 7)		All (n = 20)
Adverse effect	All grades, no. (%)	Grade 3/4, no. (%)	All grades, no. (%)	Grade 3/4, no. (%)	All grades, no. (%)	Grade 3/4, no. (%)	All grades, no. (%)	Grade 3/4, no. (%)
Fatigue	1 (33)	0	7 (70)	3 (30)	5 (71)	1 (14)	13 (65)	4 (20)
Nausea	1 (33)	0	7 (70)	0	5 (71)	0	13 (65)	0
Diarrhea	1 (33)	0	6 (60)	0	4 (57)	1 (14)	11 (55)	1 (5)
Vomiting	0	0	7 (70)	0	2 (28)	0	9 (45)	0
Anorexia	0	0	6 (60)	0	2 (28)	0	8 (40)	0
Abdominal pain	0	0	2 (20)	0	1 (14)	0	3 (15)	0
Constipation	0	0	0	0	0	0	0	0
Dehydration	0	0	2 (20)	0	0	0	2 (10)	0
Dizziness	0	0	0	0	0	0	0	0
Dyspepsia	0	0	0	0	0	0	0	0
Hyperglycemia	0	0	0	0	0	0	0	0
Hyponatremia	0	0	0	0	0	0	0	0
Generalized muscle weakness	0	0	0	0	0	0	0	0